Recent Updates
Recently added Catalysts
PRAX

Praxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment Conference

Key Takeaway: BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in
Price reaction · baseline $43.5 (2022-09-06 close) · hit after-hours · clean, no other PRAX news in the window
day 0 close
+9.3%
day 1 · peak
+16.6%
day 3
+3.8%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+61%
120-day peak, hindsight
Typical move
23.7%
average across 12 past catalysts
Cash runway
~53 mo
Minimal dilution risk
Lead asset
vormatrogine
Phase 3 · Epilepsy, Tonic-Clonic

Full Press Release Details

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 10:30 a.m. ET.
The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.
Last updated: Sep 7, 2022